Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2022-0012
Abstract: In luminal gastrointestinal tumors, immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1 and CTLA-4 have been investigated in multiple settings. The indications for these drugs are primarily dependent on specific biomarkers that imply immunogenicity: overexpression of PD-L1,… read more here.
Keywords: checkpoint inhibitors; luminal gastrointestinal; immune checkpoint; gastrointestinal malignancies ... See more keywords